Investment Strategy Brief — 2026-06-06 투자 전략
Here’s the latest scoop from brokerage reports on our holdings. Key highlights include signs of profit recovery for Hanon Systems, massive venture wins for Kakao, and Krafton’s push into multi-content platforms.
Investment Strategy Brief — 2026-06-06
Blue-chips and Core Holdings Report
Hanon Systems — Target price 4,200 KRW, restructuring in progress
Analysts note that while Hanon Systems is seeing improved profitability through cost restructuring, the company is still weighed down by high interest expenses and overhang risks related to the second-largest shareholder's stake.
Kakao — 2.2 trillion KRW profit from venture bets
Kakao Ventures, which invested 3.5 billion KRW into Dunamu 13 years ago, recently saw a return of approximately 2.2 trillion KRW—633 times their initial investment—following a partial stake sale. The firm has successfully backed five unicorns, including Carrot and Neudi (Neurofit and similar startups), proving the success of their early AI and deep-tech investment strategy.
Seegene — #1 in life science services brand reputation
Seegene ranked first in the June 2026 brand reputation index for listed life science service companies, surging 31%. The company is seeing a recovery in margins for its non-respiratory product lines and has maintained a profit-making streak for two consecutive years.
IT/Gaming Sector Analysis
Krafton — Expanding into ads, AI, and robotics
Krafton is transforming from a pure gaming company into a comprehensive digital content powerhouse, spanning advertising, AI, and robotics. Advertising accounted for over 20% of their total revenue in Q1 this year, and they are leveraging integrated app development to boost synergy between their titles.
Additionally, "Real Cricket" has seen record-breaking monthly downloads and revenue in India following its launch in time for the IPL 2026 season, marking strong growth in that market.
Kakao Games — Signs of leadership changes
Kakao Games is holding an extraordinary general meeting of shareholders on June 22 to push for the replacement of Kim Tae-hwan (Vice President at Line Games) and Lee Si-woo (Chief Business Officer at Kakao Games).
Bio and Tech Growth Stocks
ViGenCell — Clinical trial expectations
ViGenCell has seen a recent uptick in price driven by anticipation surrounding clinical trials. The company is preparing to release Phase 2 clinical results for its immune cell therapy "VT-EBV-N," further solidifying its position as a specialist in the domestic immune cell therapy market.
Comprehensive Investment Outlook
Waiting for more data: The information gathered so far reflects short-term trends and earnings improvements for individual stocks. While Hanon Systems’ cost improvements, Kakao’s venture profit, Krafton’s diversification, and Seegene’s margin recovery are seen as positive signals, risks such as financial health concerns and management reshuffles remain.
To make a well-rounded investment decision regarding macro conditions and our overall portfolio, we need to wait for further updates from upcoming brokerage reports and earnings releases.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
